Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference
“We are honored and excited that the ongoing progress of our scientific investigators and advisors showcases the differentiated benefits of Nano-Pulse Stimulation technology and helps clinicians envision the promise of an elegant solution that clears hard-to-treat skin lesions for their patients,” said Ed Ebbers, EVP and General Manager, Dermatology, of Pulse Biosciences.
To date, close to 700 patients and more than 3,600 lesions have been successfully treated in clinical studies using NPS technology delivered by the CellFX System. These studies include a spectrum of common skin lesions, notably Sebaceous Hyperplasia, non-genital Warts, Seborrheic Keratoses, Acne, Nevi and nodular Basal Cell Carcinoma.
The company recently announced its quarterly progress on its clinical and regulatory objectives. “The clinical evidence supporting the utility of NPS technology delivered by the CellFX System continues to grow as a result of the investigational use by a broad group of aesthetic dermatology key opinion leaders,” said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. “We continue to advance towards our goal of commercialization of the CellFX System in the aesthetic procedure market and are positioned to potentially receive regulatory clearances in three strategic geographies: the U.S., the European Union and Canada, as early as the end of the first quarter of 2021. We believe this growing library of clinical evidence will play a critical role in the future adoption of our technology.”
Virtual Podium Presentation
“Nano-Pulse Stimulation Technology” by Dr. Suzanne Kilmer, Founder of the Laser & Skin Surgery Center of Northern California
Saturday, December 5, 4:13pm-4:23pm Eastern Time
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more please visit www.pulsebiosciences.com.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences’ expectations regarding regulatory clearance and the timing of FDA and other regulatory filings or approvals, including meetings with FDA and the ability of the Company to successfully complete a 510(k) submission for the CellFX System or for a specific indication for the treatment of sebaceous hyperplasia (SH) lesions, the ability of the Company to prepare and provide data to FDA and other regulatory bodies, NPS technology including the effectiveness of such technology and the effectiveness of related clinical studies in predicting outcomes resulting from the use of NPS technology, the CellFX System including the benefits of the CellFX System and commercialization of the CellFX System, current and planned future clinical studies and the ability of the Company to execute such studies and results of any such studies, other matters related to its pipeline of product candidates, the Company’s market opportunity and commercialization plans, including the market for the treatment of SH, future financial performance, the impact of COVID-19 and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Source: Pulse Biosciences, Inc.